Kreiskliniken Reutlingen GmbH
- Address
- Steinenbergstrasse 31, Ringelbach, 72764 Reutlingen, Germany
Kreiskliniken Reutlingen GmbH - Comprehensive Oncology Research Center
Kreiskliniken Reutlingen GmbH is a leading clinical research institution with extensive expertise in gastrointestinal and breast cancer trials. The center demonstrates particular strength in investigating novel immunotherapy combinations, targeted therapies, and perioperative treatment strategies across multiple cancer types. Their research portfolio reflects a commitment to advancing organ-preservation approaches and personalized medicine through participation in cutting-edge phase II and III clinical trials.
- Gastrointestinal malignancies including esophageal, gastric, gastroesophageal junction adenocarcinoma, colorectal cancer, and cholangiocarcinoma
- Breast cancer research focusing on triple-negative and HER2-negative subtypes with neoadjuvant and adjuvant treatment strategies
- Hematologic malignancies including aggressive B-cell lymphomas and follicular lymphoma
- Advanced immunotherapy trials combining checkpoint inhibitors with chemotherapy, targeted agents, and bispecific antibodies
The center's research initiatives emphasize biomarker-driven patient selection and innovative treatment combinations, including FGFR-targeted therapies, KRAS G12C inhibitors, and antibody-drug conjugates. Their participation in multicenter trials investigating perioperative chemotherapy, organ preservation protocols, and post-resection maintenance strategies positions them at the forefront of optimizing treatment sequencing and improving long-term outcomes for patients with locally advanced and metastatic cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 50 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kreiskliniken Reutlingen GmbH
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Durvalumab-Based Immunotherapy with Chemoradiation for Organ Preservation in Early-Stage cT1-cT2N0 Esophageal Adenocarcinoma | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Phase II | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 8 | Unknown | 2018-09-03 | 2025-08-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.